AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00769366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: humanistic-existential psychotherapy conducted in individual and group meetings
Study NCT00769366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy
Description: Optimal medical therapy after Acute myocardial infarction
Study NCT03768219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is saline based IV infusion, and is identical in appearance to active study drug.
Study NCT01537575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravenous immunoglobulins
Description: One course of Intravenous Immunoglobulins 0.4 g/kg/die for 5 consecutive days
Study NCT01537575 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Placebo
Study NCT02864082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAT-001, 0.1%
Description: PAT-001 is a topical ointment. PAT-001, 0.1% contains 0.1% of active drug.
Study NCT02864082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAT-001, 0.2%
Description: PAT-001 is a topical ointment. PAT-001, 0.2% contains 0.2% of active drug.
Study NCT02864082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle for PAT-001 0.1%
Description: Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.1%.
Study NCT02864082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle for PAT-001 0.2%
Description: Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.2%.
Study NCT01281579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: Tablets, oral, 100-mg, once daily on Day 1 and on Days 4 through 9.
Study NCT01281579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg
Description: Tablets, oral, 50-mg, once daily on Day 1 and on Days 4 through 9.
Study NCT01281579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: Tablets, oral, 300-mg, once daily on Day 1 and on Days 4 through 9.
Study NCT06321666 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: WB-MRI
Description: All patients will undergo a CT scan (neck/thorax/abdomen/pelvis) and a WB-MRI
Study NCT03569254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neomedlight Phototherapy Blanket
Description: The NeoMedLight® phototherapy blanket is an innovative new fiber-optic device based on LED light. Its light emitting surface area is 40.5x30 cm or 1200 cm2. The device size is 40.5 x30 cm. It incorporates fiber optic mesh and is protected by a vinyl cover and a disposable liner for patient comfort and hygiene. This device provides therapeutic light (404-515nm) to a wide extension of the body surface area. Its average irradiation footprint is 35uW / cm2 / nm ± 15%. The phototherapy was done intermittently in periods of 2 hours with 1 hour of rest for a total time of 6 hours in kangaroo position.
Study NCT03569254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ohmeda-Fiber Optic Phototherapy Blanket
Description: This device is a high performance version of Ohmeda Medical's Biliblanket that uses a fiber optic cable to deliver light from a high-intensity lamp to a device composed of a fiber optic fabric. The device has a disposable liner and is left in direct contact with the patient. The patient is exposed to a light with a wavelength between 400 and 550 nanometers. The phototherapy system consists of a light emitting unit, a fiber optic cable four feet long (121.9 cm) and a lightweight mattress. It has two available sizes: 4.38 x 9.38 inches (11.12 x 23.83 cm) and 4.00 x 6.00 inches (10.16 x 15.2 cm).
Study NCT03759873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Patient earns financial incentives (gift cards) on an escalating schedule for completing cardiac rehabilitation sessions.
Study NCT03759873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case Management
Description: A case manager is available by phone to assist patient with attending cardiac rehabilitation sessions as well as to provide advice about cardiac symptoms and healthy behavior change.
Study NCT04429490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adipose tissue sampling during surgery and urine sampling
Description: Adipose tissue sampling during surgery and urine sampling
Study NCT04429490 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Adipose tissue sampling during surgery and urine sampling
Description: Adipose tissue sampling during surgery and urine sampling
Study NCT01127178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7016 + TMZ
Description: Single-Dose PK Period (single oral dose of E7016 on Day -7) in the Dose-Escalation Component; Multiple-Dose Treatment Cycles (7 days of oral E7016 + 5 days of oral TMZ) added in Cycle 1 of the Dose-Escalation Component and in Cycles 1 through 6 of the Expansion Component.
Study NCT02758431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acyline
Description: Acyline 300ug/kg injection will be administered on Day 0 and on day 14
Study NCT02758431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyline
Description: Acyline 300ug/kg injection will be administered on Day 0 and on day 14
Study NCT02758431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Placebo gel packet applied daily for 28 days.
Study NCT02758431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo oral tablet taken daily for 28 days.
Study NCT02758431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo oral tablet taken daily for 28 days.
Study NCT02758431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel
Description: Testosterone Gel applied daily for 28 days
Study NCT02758431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arimidex
Description: Arimidex Oral Tablet 1mg taken orally daily for 28 days
Study NCT03370887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8601
Description: AZD8601 solution for injection, 0,5 mg/mL and 5 mg/mL will be given as 30 injections of 0.1 mg (3 mg per patient), or 1 mg (30 mg per patient) respectively on a single occasion
Study NCT04088578 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Training
Description: Controlling movement of an object on computer screen by adjusting muscle activity.
Study NCT04088578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Controlling movement of an object on computer screen by adjusting muscle activity.
Study NCT04088578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation
Description: Recruits the auricular branch of the vagus nerve which activates brain structures that release chemicals mediating cortical plasticity.
Study NCT04088578 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sub-threshold stimulation that does not activate neural structures.
Study NCT04670822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion
Description: The intervention group will receive multicomponent interventions consisting of 7 half-hour postnatal visits for lactation counseling, family/peer/employer support, contingent financial incentives, and early limited formula milk via syringe (optional for at-risk infants).
Study NCT04670822 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention placebo control
Description: The attention placebo control group will complete the same frequency and duration of study visits as the intervention group but focus on general infant care counseling and support.
Study NCT01207128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole, micafungin
Description: Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous (IV)Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and gastrointestinal functions are intact.
Study NCT03668028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TPX-114
Description: Subjects will be treated with autologous fibroblasts (TPX-114) during arthroscopic surgery.
Study NCT03668028 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Arthroscopic surgery
Description: Subjects undergo conventional arthroscopic surgery for rotator cuff repair.
Study NCT03668028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery
Description: Subjects undergo conventional arthroscopic surgery for rotator cuff repair.
Study NCT02262949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeStent Vascular Stent
Description: PTA followed by implantation of the LifeStent Vascular Stent (stent length 250 mm) in the SFA or popliteal artery.
Study NCT01567371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiDCO rapid monitor
Description: Technology which provides a continuous means of monitoring various hemodynamic parameters including cardiac output and pulse pressure variability.
Study NCT02622074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg administered Q3W as an IV infusion.
Study NCT02622074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 125 mg/m\^2 or 100 mg/m\^2 administered weekly as an IV infusion, according to allocation.
Study NCT02622074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthracycline (doxorubicin)
Description: 60 mg/m\^2 administered Q3W as an IV injection.
Study NCT02622074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m\^2 administered Q3W as an IV infusion.
Study NCT02622074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6 or AUC5 administered Q3W as an IV infusion, or AUC2 administered weekly as an IV infusion, according to allocation.
Study NCT02622074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 or 70 mg/m\^2 administered weekly as an IV infusion, according to allocation.
Study NCT03994588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal Mesh hernia repair
Description: The mesh will be inserted intraperitoneally for complex ventral hernia repair and fixed according the previously described ADMIR technique.
Study NCT03370887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for AZ8601 injection for solution will be given as 30 injections per patient on a single occasion
Study NCT04445818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: More appreciation
Study NCT04445818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Less criticism
Study NCT04445818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: More Fruit and Vegetable
Study NCT00784043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implant
Description: Bilateral Implantation in children
Study NCT03487835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Study NCT03487835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No application
Description: This group have no application during study time
Study NCT01357798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Botulinum Toxin group Will have the syringe with Botulinum toxin type A . During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution.
Study NCT01357798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0,9% saline
Description: 0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
Study NCT03793985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T
Description: CKD-391 40/10mg
Study NCT03793985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T
Description: CKD-391 40/10mg
Study NCT03793985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R
Description: D086 and D337 co-administration
Study NCT03793985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R
Description: D086 and D337 co-administration
Study NCT02116634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell
Description: intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
Study NCT04003649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
Description: Given ITV/ITC
Study NCT00593138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dex-methylphenidate
Description: The drug is administered as a capsule by mouth. Participants are assigned to receive either 20, 30 or 40 mg doses before each scan visit.
Study NCT01681043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: protocol 'Quiet in the room'
Description: Protocol 'Quite in the room' between 10 p.m. and 6 a.m.~* nurse nearby~* no visits after 10 p.m.~* decreased alarm sound in ventilator and monitor~* decreased light intensity~* no unnecessary conversations around the patient~* medication should be limited to max 1-2 times in this time period~* no unnecessary therapeutic or diagnostic procedures in this time period~* earplugs and sleep masks
Study NCT04003649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT04003649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04003649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04003649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01440478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally
Study NCT03610204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buffalo horn technique
Description: The participants receive a 30-min massage session, twice a week for a total 6 sessions.
Study NCT03610204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Buffalo horn technique
Description: The participants receive a 30-min massage session, twice a week for a total 6 sessions.
Study NCT03862313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active-rtACS treatment
Description: For the active-rtACS treatment arm, a CE-certificated proprietary class IIa medical device will be used to apply transorbital symmetrical rectangular current pulses in bursts (NextWave® 1.1 system; EBS Technologies GmbH, Germany). The stimulation protocol will be patient-individualized, with a stimulation current strength of 125% of the phosphene threshold recorded during 5Hz stimulation and stimulation frequencies between the individual's EEG alpha frequency and their flicker fusion frequency.
Study NCT01440478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ammonium chloride
Description: Administered orally
Study NCT01440478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Administered orally
Study NCT00879970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: Pioglitazone30 mg and 45 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
Study NCT00879970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone
Description: Rosiglitazone 4 mg and 8 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
Study NCT00879970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo to match is Swedish orange size DB-AA capsule filled with white to off-white non-active powder blend.
Study NCT00879970 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D factor intervention
Study NCT00879970 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vitamin D factor intervention
Study NCT00592020 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short Transverse Incision
Description: Short Transverse Incision for kidney transplantation
Study NCT00592020 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hockey Stick Incision
Description: Hockey Stick Incision for kidney transplantation
Study NCT03295058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non ATG Conditioning regimen
Description: 50% of the patients will receive Fludarabine + cyclophosphamide (F-araA 120 mg/m2 total dose for 3 days (d-3,-2,-1) over 1 h infusion and cyclophosphamide 25 mg/kg/d (d-5 to d-2) for 4 days over 1-h infusion prior to hematopoietic cell transplantation , then post transplant cyclophosphamide dose 50 mg/kg on days +3 and +4
Study NCT03295058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD Prophylaxis
Description: Cyclosporine A (CsA 3 mg/kg) start day +5
Study NCT03295058 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogenic Stem Cell Transplantation
Description: using peripheral blood stem cells
Study NCT03295058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG conditioning regimen
Description: the other 50% of the patients will receive Cyclophosphamide + ATG
Study NCT01809795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blueberry Smoothie
Study NCT03862313 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-rtACS treatment
Description: For the sham-rtACS treatment arm, exactly the same medical device, setup, time schedule, etc. will be used as for the patients of the active-rtACS arm. However, sham-treated patients will receive no actual current stimulation during the therapy sessions.
Study NCT02362360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test Product
Description: A new 2-piece ostomy appliance developed by Coloplast A/S
Study NCT01809795 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Smoothie
Study NCT01504867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 325mg loading dose once on study day 1, followed by 81mg dose once daily on study days 2-7. Administered by mouth or down nasal gastric tube.
Study NCT01504867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose powder
Description: Matching lactose powder filled capsules will be administered on days 1-7.
Study NCT01736813 — intervention group
Intervention type: DRUG
Intervention: Maraviroc
Description: Twelve patients with 300 mg/bid
Study NCT02032472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of Arterial Pressure
Description: Pharmacies cooperate in measuring blood pressure of patients
Study NCT03955393 — intervention group
Intervention type: OTHER
Intervention: 18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS
Description: 18F-FAZA is a highly selective PET radiotracer of hypoxia, which has been recently developed and tested in several studies (10-14). 18F-FAZA has been demonstrated to be a marker of hypoxia and pathological metabolic patterns which are common to all renal cancers.
Study NCT02758587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: cross reference with arm/group descriptions
Study NCT02758587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: cross reference with arm/group descriptions
Study NCT02529800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1402
Description: Tamsulosin HCl 0.4mg
Study NCT02529800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0412
Description: Tamsulosin HCl 0.2mg
Study NCT02362360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator (Hollister)
Description: Comparator is a Hollister FlexWear baseplate (ileostomy) or a Hollister SoftFlex baseplate (colostomy) both used with a Hollister open bag.
Study NCT02450201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyruvate
Study NCT00914797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled and oral terbutaline
Description: Inhalation of 2 mg terbutaline as powder as a single dosage. Oral terbutaline 10 mg as a single dosage.~Inhaled: Bricanyl Turbohaler 0.5 mg/dose, MA no. 41076.~Oral: Tablet Bricanyl Retard 5 mg, MA no. 10954.
Study NCT03376074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated perfusion (HOPE)
Description: 25 patients: Application of HOPE for 2 hours, perfusion rate 100-150 ml/min, pressure controlled, perfusion pressure \< 3 mm Hg, perfusion route portal vein, recirculating system, perfusion volume 2 L, perfusate solution (UWMP®), perfusate temperature 4-12 °C, perfusate oxygenation 40 KPa